Research ArticleOpen AccessGoogle Scholar indexed
<i>STYK1/NOK</i>—A Potential Radiotherapeutic Target and Biomarker for Gastric Cancer and Cervical Cancer
Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, China Centers for Disease Control, Beijing, China
Department of Experimental Therapy of Acute Radiation Sickness, Beijing Institute of Radiation Medicine, Beijing, China
College of Life Science and Technology, Xinjiang University, Urumchi, China
The Second Artillery Journal Hospital People’s Liberation Army, Beijing, China
- 1 Key Laboratory of Radiological Protection and Nuclear Emergency, National Institute for Radiological Protection, China Centers for Disease Control, Beijing, China
- 2 Department of Experimental Therapy of Acute Radiation Sickness, Beijing Institute of Radiation Medicine, Beijing, China
- 3 College of Life Science and Technology, Xinjiang University, Urumchi, China
- 4 The Second Artillery Journal Hospital People’s Liberation Army, Beijing, China
Journal of Cancer Therapy·Volume 04 (2013)·Pages 575–577·Published 11 April 2013·DOI10.4236/jct.2013.42073
Copy link · social · email
Abstract
This article introduced the STYK 1 /NOK , including its origin, chemical composition and biological function, and the expression of STYK 1 /NOK in various cancer cell lines was reviewed. Furthermore, our recent study showed that STYK 1 /NOK protein was also over expressed in gastric cancer and cervical cancer specimens, and STYK 1/ NOK expres sion increased after tumor cells were irradiated with γ ray. These results indicated that STYK 1/ NOK might be involved in the occurrence and progress of gastric cancer and cervical cancer, and contribute to the radioresistance of tumor cells. Thus, STYK 1/ NOK might be a potential therapeutic target and diagnostic marker for gastric cancer and cervical cancer.
KeywordsGastric CancerCervical Cancer<i>STYK1/NOK</i>Therapeutic Target
- L. Liu, X. Z. Yu, T. S. Li, L. X. Song, P. L. Chen, T. L. Suo, Y. H. Li, S. D. Wang, Y. Chen, Y. M. Ren, S. P. Zhang, Z. J. Chang and X. Y. Fu, “A Novel Protein Tyrosine Kinase NOK That Shares Homology with PlateletDerived Growth Factor/Fibroblast Growth Factor Receptors Induces Tumorigenesis and Metastasis in Nude Mice,” Cancer Research, Vol. 64, No. 10, 2004, pp. 3491-3499. doi:10.1158/0008-5472.CAN-03-2106
- J. Li, F. Wu, F. Sheng, Y. J. Li, D. Jin, X. Ding and S. Zhang, “NOK/STYK1 Interacts with GSK-3β and Mediates Ser9 Phosphorylation through Activated Akt,” FEBS Letters, Vol. 586, No. 21, 2012, pp. 3787-3792. doi:10.1016/j.febslet.2012.09.011
- K. S. Kimbro, K. Duschene, M. Willard, J. A. Moore and S. Freeman, “A Novel Gene STYK1/NOK Is Upregulated in Estrogen Receptor-Alpha Negative Estrogen Receptor-Beta Positive Breast Cancer Cells Following Estrogen Treatment,” Molecular Biology Reports, Vol. 35, No. 1, 2008, pp. 23-27. doi:10.1007/s11033-006-9047-1
- T. Amachika, D. Kobayashi, R. Moriai, N. Tsuji and N. Watanabe, “Diagnostic Relevance of Overexpressed mRNA of Novel Oncogene with Kinase-Domain (NOK) in Lung Cancers,” Lung Cancer, Vol. 56, No. 3, 2007, pp. 337-340. doi:10.1016/j.lungcan.2007.01.002
- D. M. Roder, “The Epidemiology of Gastric Cancer,” Gastric Cancer, Vol. 5 Suppl 1, 2002, pp. 5-11.
- B. Zilberstein, C. E. Jacob and I. Cecconello, “Gastric Cancer Trends in Epidemiology,” Arquivos de Gastroenterologia, Vol. 49, No. 3, 2012, pp. 177-178. doi:10.1590/S0004-28032012000300001
- P. Correa, M. B. Piazuelo and M. C. Camargo, “The Future of Gastric Cancer Prevention,” Gastric Cancer, Vol. 7, No. 1, 2004, pp. 9-16. doi:10.1007/s10120-003-0265-0
- T. Nakajima, “Gastric Cancer Treatment Guidelines in Japan,” Gastric Cancer, Vol. 5, No. 1, 2002, pp. 1-5. doi:10.1007/s101200200000
- J. Schiedel, A. Blaukat, S. Li, et al., “Matuzumab Binding to EGFR Prevents the Confomational Rearrangement Required for Dimerization,” Cancer Cell, Vol. 13, No. 4, 2008, pp. 365-373.
- Y. Matsui, M. Inomata, M. Tojigamori, et al., “Suppression of Tumor Growth in Human Gastric Cancer with HER2 Overexpression by an Anli-HER2 Antibody in a Murine Model,” International Journal of Oncology, Vol. 27, No. 3, 2005, pp. 68l-685.
- K. Fujimoto-Ouchi, F. Sekiguchi, H. Yasuuno, et al., “Antitumor Activity of Trustuzumab in Combination with Chemothempy in Human Gastric Cancer Xenograft Models,” Cancer Chemotherapy and Pharmacology, Vol. 59, No. 6, 2007, pp. 795-805.